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It has been reported that cord blood transplantation (CBT) for patients with aggressive adult T-cell 
leukemia/lymphoma (ATL) results in poorer outcomes than transplantation using other stem cell sources. 
To identify a subset of ATL in which CBT is feasible, we retrospectively analyzed 27 patients treated with 
CBT at three institutions in Nagasaki Prefecture, Japan. The estimated overall survival (OS) rate at three 
years was 27.4%. Of 16 patients that received CBT during remission (complete, CR, or partial, PR), the 
OS rate at three years was 50%, while during refractory periods (non-CR or non-PR), the OS rate was 
9.1%. Reduced intensity conditioning (RIC) was given to 18 patients, and myeloablative conditioning 
(MAC) was used in nine, with 3-year OS of 50.0% and 0%, respectively. Of the 19 deaths, nine were due 
to progressive disease, eight (five MAC and three RIC) to infection, and two to multiple organ failure. 
These results suggest that CBT provides similar results with those in other transplantation procedures for 
selected ATL patients, such as those in CR or PR. Further studies are needed to evaluate the use of CBT 
in aggressive ATL. 
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Introduction 
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been applied as a curative option to 
patients with aggressive ATL [1, 2]. Several reports have demonstrated that allo-HSCT from related and 
unrelated peripheral blood (PB) or bone marrow (BM) is effective for ATL with a 3-year overall survival 
(OS) between 30 to 40%, despite high transplant-related mortality (TRM) rate [3-8]. It was also shown 
that allo-HSCT could provide long-term survival for some patients with aggressive ATL probably 
associated with graft-versus-lymphoma (GVL) effects [9]. 
A recent nationwide retrospective study of allo-HSCT in 386 patients with ATL based on the registry data 
of the Japan Society for Hematopoietic Cell Transplantation, the Japan Marrow Donor Program (JMDP) 
and the Japan Cord Blood Bank Network demonstrated that the 3-year OS of cord blood transplantation 
(CBT) is inferior to that of HLA-matched related and unrelated transplantation (17% vs 41% and 39%, 
respectively), and CBT was one of the four recipient factors associated with lower survival rate [8]. The 
same group also reported the effect of graft-versus-host disease (GVHD) and the intensity of conditioning 
regimen (reduced intensity conditioning, RIC, myeloablative conditioning, MAC) in allo-HSCT for ATL. 
They showed that grade I/II acute GVHD was associated with improved survival after allo-HSCT 
(including CBT) for ATL. The beneficial effect of mild acute GVHD was selected by multivariate 
analysis, suggesting that it would work in the setting of CBT as well [9]. Interestingly, the intensity of 
conditioning before transplantation did not have a significant impact on the overall survival for ATL 
patients that received allo-HSCT using BM or PB as stem cell sources [10], although HSCT with RIC 
was significantly associated with ATL-related mortality. 
Based on these reports, we thought that there might be a subset of ATL patients for which CBT could 
provide survival benefit, probably through graft-versus-ATL (GvATL) effect. To evaluate this possibility, 
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we analyzed retrospectively our experiences of CBT for 27 ATL patients in the Nagasaki Transplantation 
Network. We could demonstrate that there were several long-term survivors after CBT, and that CBT 
might be an option for selected ATL patients such as those within clinical remission. 
 
Patients and method 
Study design and data collection 
Between October 2004 and July 2010, 27 patients with aggressive ATL underwent CBT using both 
myeloablative and reduced-intensity conditioning at three institutions in Nagasaki prefecture. Data were 
collected and updated in September 2011. Three patients were included in a previous report of a 
nationwide retrospective study of the allo-HSCT for ATL by Hishizawa et al. [8], and the data of two of 
these patients were updated. Before the transplantation procedure, all patients received conventional 
chemotherapy including anthracyclines. The median duration from diagnosis to transplantation was 114 
days (range: 56–481 days).  
 
Transplantation 
Of the 9 patients who received MAC, 3 received cyclophosphamide (CY; 60 mg/kg i.v. daily for 2 days) 
and busulfan (BU; 4 mg/kg p.o. or 3.2 mg/kg i.v. daily for 4 days), and 6 received CY and total body 
irradiation (TBI; total 12 Gy, 6 fractions) with or without cytarabine (2 g/m2 i.v. for 4 days). All 18 
patients except one in RIC group received fludarabine (FLU) and melphalan (MEL) with or without TBI 
regimen. 13 received FLU (25 mg/m2 i.v. daily for 5 days), MEL (80 mg/m2 i.v. for one day), and TBI (4 
Gy), 4 received FLU and MEL, and 1 received FLU, BU (3.2 mg/kg i.v. daily for 2 days) and TBI (2 Gy). 
Prophylaxis against GVHD was as follows: tacrolimus (Tac), n=12; Tac and methotrexate (MTX), n=7; 
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cyclosporine A (CyA) and MTX, n=7; and CyA only, n=1 (Table 1).  
 
Statistical analysis and definition 
OS was measured from day 0 of transplantation until death from any cause or the last known follow-up. 
TRM was defined as all causes of non-relapse death after transplantation. Response was judged using 
Japan Clinical Oncology Group criteria for ATL as described [11, 12]. Survival curves were estimated 




Clinical characteristics of the patients are summarized in Tables 1 and 2. All patients had aggressive ATL 
(17 acute and 10 lymphoma). Median age was 52 (range: 41–63) years. Sixteen patients showed a clinical 
response to prior chemotherapy (5 complete remission, 10 first partial remission (PR), and 1 second PR). 
These patients were categorized as being “chemosensitive”, while others were as “refractory” to 
chemotherapy. Number of chemosensitive patients was 4 and 12, and that of refractory patients was 5 and 
6 in the MAC group and RIC group, respectively. 
 
Engraftment 
All patients received a cord blood cell infusion of over 2 x 107/kg (median 2.75; range: 2.00–4.28 x 
107/kg). All cord-blood grafts, except one, were HLA-mismatched; 4 with one antigen mismatch, and 22 
with two antigens. Two patients did not achieve engraftment because of early relapse, and three patients 
were not evaluable because of early treatment-related mortality before engraftment. A total of 22 patients 
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achieved neutrophil regeneration, and the median number of days was 20 (range: 13–98 days). 
 
Overall outcome 
The median survival time of all cases after transplantation was 192 days (range: 6–2530 days), and the 
median observation time of the 8 surviving patients was 1079.5 days (range: 666–2530 days) at the time 
of analysis (September 2011). The estimated OS rate at 3 years in all cases was 27.4% after 
transplantation (Figure 1). The OS rate at 3 years in the chemosensitive group (CR and PR, 16 patients) 
and refractory group (primary induction failure and relapse, 11 patients) was 50.0% and 9.1%, 
respectively, while that in the RIC group and MAC group was 50.0% and 0%, respectively (Figures 2 and 
3). 
 
Cause of death 
After transplantation, 19 patients died; 9 due to progressive disease (PD) and 10 due to TRM. Of the 10 
TRM deaths, 8 were due to infection (5 bacterial, 2 adenovirus, and 1 cytomegalovirus pneumonia), and 2 
were due to multi-organ failure (MOF). All 9 patients who received MAC died; 6 due to TRM (5 
infections and 1 MOF) and 3 due to progressive disease (PD). Of the 4 patients with chemosensitivity in 
the MAC group, 2 died due to PD and 2 to infection. Of the 18 patients who received RIC, 10 patients 
died. There were 6 deaths (5 PD and 1 MOF) among the 13 patients who received FLU, MEL, and TBI, 3 
deaths (2 infections and 1 PD) among the 4 patients who received FLU and MEL, and 1 death (infection) 
of a patient who received FLU, BU, and TBI. Within 6 months after transplantation, there were 6 deaths 
(4 infections, 1 MOF and 1 PD) in patients who received MAC and 7 deaths (3 infections, 1 MOF and 3 
PD) in patients who received RIC. 
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Graft-versus-host disease 
A total of 8 patients developed acute GVHD at a median of 28 days (range: 14–46 days); 3 with grade I, 4 
with grade II, and 1 with grade IV. All four patients with grade II acute GVHD improved spontaneously. 
Only the grade IV patient received immunosuppressive treatment and improved. No GVHD was 
implicated in any deaths. Chronic GVHD was observed in 3 patients and was developed from acute 
GVHD; extensive type in 2 patients and limited type in 1. Among the 3 patients with chronic GVHD, 2 
survived without relapse for 2.3 and 1.8 years. The other patient survived after relapse for 0.7 years and 
finally died due to PD. 
 
Long-term survivors 
Eleven patients survived more than one year (Table 2). After transplantation, the median follow-up period 
was 2.3 years, and the longest follow-up period was 6.9 years. Eight and 3 patients were in 
chemosensitive and refractory group, respectively. Ten patients received RIC (9 with FLU, MEL, and TBI 
4 Gy, and 1 with FLU and MEL), and only 1 patient received MAC. A total of 8 patients survived for a 
median of 3.0 (1.8-6.9) years. Of these 8 patients 7 were in chemosensitive group and all received RIC. 
Three of 4 patients who survived more than 3 years were also in chemosentisitive group. One patient who 
relapsed after 45 months transplantation achieved another CR by local radiation therapy and was alive 5 
years after transplantation. 
 
Discussion 
Previous studies reported that there was no difference in the outcome after allo-HSCT using CB 
compared that using HLA-matched [13] or HLA-mismatched [14] unrelated transplantation for adults 
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with acute leukemia. ATL was not included in these studies, however, in a nationwide retrospective study 
of allo-HSCT for ATL in Japan, the 3-year OS rate after CBT of 17% was significantly inferior to that of 
HLA-matched unrelated and mismatched related transplantation by 39% and 24%, respectively [8]. The 
reasons for the poor outcome of CBT for ATL were considered to be high incidence of TRM, especially 
with fatal infectious complications [3], that was related to the preexisting profound immunodeficiency of 
ATL [15, 16] . 
The 3-year OS rate of CBT was 27.4 % in our study with several long-term survivors. Eight out of the 11 
patients who survived more than one year showed chemosensitivity and received transplantation during 
CR or PR. This resulted in the difference of OS between chemosensitive (3-year OS, 50.0%) and 
refractory (3-year OS, 9.1%) patients (Figure 2). Considering that CBT during refractory status of ATL 
ended in poor outcome (5 cases of TRM, and 5 of PD), it suggested that CBT could provide reliable 
efficacy for limited ATL patients that were associated with chemosensitivity. 
We also found that RIC showed better OS than MAC in our analysis (3-year OS of 50% and 0%, 
respectively, Figure 3). It has been reported that CBT after MAC is safe and effective treatment for adult 
patients with hematologic malignancies [17, 18], which did not include ATL. In our analysis, 6 out of 9 
patients that received MAC died with TRM, although there was no highly intensified conditioning 
regimen in MAC. The difference of TRM in the MAC group (6 of 9 patients) and RIC group (3 of 18 
patients) seemed stem from the uneven distribution of chemosensitive patients; chemosensitive patients 
were biased in RIC group (12 out of 18, and 4 out of 9 in RIC and MAC, respectively). This is the 
limitation of our study with small number of cases to evaluate the relationship of the effect of 
chemosensitivity and conditioning regimen. A recent nationwide retrospective study of allogeneic bone 
marrow and peripheral blood stem cell transplantation for ATL in Japan with special emphasis on the 
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effect of the preconditioning regimen revealed that TRM in MAC was higher than in RIC and that RIC 
was more significantly associated with ATL-related mortality than MAC, although no significant 
difference in OS between MAC and RIC recipients was observed [10]. RIC might provide long-term 
survival by reducing TRM. 
It was previously reported that GvATL effect might affects long-term survival of patient with ATL after 
allo-HSCT from related marrow and periperal blood and unrelated marrow donors [1, 3, 5]. Recent report 
by Kanda et al. demonstrated that the development of mild-to-moderate acute GVHD confers a lower risk 
of disease progression and a beneficial influence on survival in allografted patients with ATL [9], which 
was in accordance with previous data [1, 3, 5]. In the present study, one patient that relapsed after CBT 
had achieved another CR only by local radiation therapy, and survived more than two years. With a 
suggestive anti-lymphoma effect after CBT for a patient with peripheral T-cell lymphoma and mycosis 
fungoides [19], CvATL effect could also work after CBT for ATL. 
Our results suggested that CBT could be feasible treatment for selected patients with ATL, probably those 
with chemosensitivity. Further clinical studies for the development of proper indication of CBT, an 
effective transplant procedure including a preconditioning regimen are needed. For this purpose, a clinical 
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Figure 1. Kaplan-Meier estimates of overall survival after cord blood transplantation for all patients with 
ATL. 
 
Figure 2. Kaplan-Meier estimates of overall survival after cord blood transplantation according to 
chemosensitivity. 
 





Table 1.Patinet characteristics and transplant condition 
Sex (male/female) 18/9 
Median age at transplant (range) 52 (41-63) 
Subtype of ATL  
Acute 17 
Lymphoma 10 






Conditioning regimen  
CY 120mg/kg, BU 16 or 12.8mg/kg 3 
CY 120mg/kg, TBI 12Gy with or without CA 8g/m2 6 
FLU 125mg/m2, MEL 80mg/m2, TBI 4Gy 13 
FLU 125mg/m2, MEL 80mg/m2 4 
FLU125mg/m2, BU 6.4mg/kg, TBI 2Gy 1 
Prophylaxis against GVHD  
CsA 1 
TCR 12 
CsA + sMTX 7 
TCR + sMTX 7 
HLA compatibility  
Matched  1 
One-antigen mismatch 4 
Two-antigen mismatch 22 
Nucleated-cell dose/kg of body weight-x 107 2.75 (2.00-4.28) 
CR1 first complete remission, PR1 first partial remission, PR2 second partial remission, PIF primary 
induction failure, REL refractory after relapse, CY cyclophosphamide, BU busulfan, CA cytarabine, FLU 
fludarabine, MEL melphalan, TBI total body irradiation, CsA cyclosporine, TCR tacrolimus, sMTX short 
term methotrexate 
Table 2. Characteristics and results of hematopoietic stem cell transplantation of the 27 patients with ATL 
No. age sex subtype Disease status at transplant Conditioning regimen 
GVHD 







1 45 male acute PR1 FLU+MEL+TBI CsA+sMTX - - - 6.9a 
2 59 female acute PR1 FLU+MEL+TBI TCR - - 3.8 5.8a 
3 61 male lymphoma CR1 FLU+MEL+TBI TCR I - - 4.3a 
4 55 female lymphoma PIF FLU+MEL+TBI TCR+sMTX - - - 3.1a 
5 54 female acute PR1 FLU+MEL TCR+sMTX - - - 2.8a 
6 54 male acute CR1 FLU+MEL+TBI TCR II extensive - 2.2a 
7 53 male acute PR1 FLU+MEL+TBI TCR+sMTX - - - 1.9a 
8 52 male acute PR1 FLU+MEL+TBI TCR+sMTX I limited - 1.8a 
9 41 male lymphoma CR1 FLU+MEL+TBI TCR II extensive 1.6 2.3 (PD) 
10 51 female lymphoma relapse FLU+MEL+TBI TCR - - 0.8 1.7 (PD) 
11 58 male acute PR1 FLU+MEL+TBI TCR+sMTX - - 0.4 0.7 (PD) 
12 56 female lymphoma relapse FLU+MEL CsA+sMTX II - 0.2 0.4 (PD) 
13 53 male lymphoma PIF FLU+MEL+TBI CsA+sMTX - - 0.2 0.4 (PD) 
14 52 male lymphoma PR1 FLU+MEL+TBI TCR+sMTX - - - 0.3 (TRM) 
15 63 male acute PR1 FLU+BU+TBI TCR - - - 0.1 (TRM) 
16 59 male acute PR1 FLU+MEL TCR - - - 0.1 (TRM) 
17 59 male lymphoma PIF FLU+MEL TCR+sMTX NE NE NE 0.1 (TRM) 
18 55 female lymphoma PIF FLU+MEL+TBI TCR NE NE refractory 0.1 (PD) 
19 44 male acute relapse CY+CA+TBI TCR - - 0.3 1.9 (PD) 
20 43 male acute CR1 CY+TBI CsA+sMTX - - - 0.6 (TRM) 
21 52 female acute CR1 CY+TBI TCR IV - 0.4 0.5 (PD) 
22 46 male acute PR2 BU+CY CsA+sMTX NE NE refractory 0.3 (PD) 
23 44 female acute relapse CY+TBI CsA+sMTX - - - 0.3 (TRM) 
24 48 male acute relapse BU+CY CsA+sMTX - - - 0.2 (TRM) 
25 45 male lymphoma PR1 BU+CY TCR I - - 0.1 (TRM) 
26 50 male acute relapse CY+TBI TCR - - - 0.1 (TRM) 
27 47 female lymphoma PIF CY+CA+TBI CsA+sMTX NE NE NE 0.1 (TRM) 
aGVHD acute graft-versus-host disease, cGVHD chronic GVHD, NE not evaluated, PD progressive disease, TRM transplant-related mortality, a patient still alive 
